Hepatocellular carcinoma (HCC) is the fifth most frequent cancer worldwide and in most cases it evolves on a cirrhotic liver, which requires a complex treatment strategy that includes different options. We present the case of a 62 years old patient, suffering from chronic HBV and HDV hepatitis, which was found, in 2011 with a 7 cm HCC located in the sixth segment of the liver and resected. Within less than a year, tumor relapse was detected (multiple nodules in the remaining sixth segment). Systemic chemotherapy (Sorafenib) started being administered and two TACE procedures were performed at one year and seven months difference. Despite that, the CT and MRI showed the evolution of the disease. The therapy was stopped and the patient was listed for liver transplantation and the procedure was performed. The thirteen months post transplantation assessment showed no sign of tumor relapse.
No takes yet. Share an insight, caveat, or question.
Grigorie et al. (2017) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: